NEUROGENESIS, INC.

Neurogenesis, Inc. Share Price

Equities

NEUN

US64124F3010

Market Closed - OTC Markets Other stock markets 19:49:55 03/05/2024 BST			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2023	Neurogenesis, Inc. Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome	CI
2021	Neurogene Inc. and University of Edinburgh Announces Research Collaboration to Advance Next Generation Gene Therapies	CI

on all our subscriptions*

Take advantage of the offer

* See conditions on site

Financials

Sales 2004	2.51M 197M	Sales 2005 *	-	Capitalization	289K 22.75M
Net income 2004	- 0	Net income 2005 *	-	EV / Sales 2004	0.55 x
Net cash position 2004	3.01K 237K	Net cash position 2005 *	- 0	EV / Sales 2005 *	-
P/E ratio 2004	84.8 x	P/E ratio 2005 *	-	Employees	-
Yield 2004 *	-	Yield 2005 *	-	Free-Float	0%

More Fundamentals * Assessed data

Chart Neurogenesis, Inc.

Duration

Period

Style

Latest news about Neurogenesis, Inc.

Neurogenesis, Inc. Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome	11-30	CI
Neurogene Inc. and University of Edinburgh Announces Research Collaboration to Advance Next Generation Gene Therapies	19/01/21	CI
Hadassah Medical Center and Neurogenesis Announce Results from a Phase 2 Study in Progressive Multiple Sclerosis treated with NG-01 Autologous Cells Therapy	08/12/20	CI
Neurogene Names Kenneth Huttner as Senior VP of Clinical Development	26/07/20	CI

Highs and lows

Current year

0.00

0.00

1 year

0.00

0.00

3 years

0.00

0.08

5 years

0.00

0.08

10 years

0.00

0.08

Managers and Directors - Neurogenesis, Inc.

Managers	Title	Age	Since
Albert H. Bieser CHM	Chairman	-	31/12/97
Karen Coady AUD	Comptroller/Controller/Auditor	-	-
Paul Brown SEC	Corporate Secretary	-	-

Members of the board	Title	Age	Since
Albert H. Bieser CHM	Chairman	-	31/12/97
Karen Coady AUD	Comptroller/Controller/Auditor	-	-

Company Profile

Sector

-

More about the company

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW